Table 2 Detailed clinical profiles of RS3PE patients with malignancy
No. | Age/sex | Type of malignancy | Time from arthritis onset to malignancy confirmation | Signs | ESR (mm/h) | CRP (mg/L) | bFGF (ng/mL) | Initial pred. (mg/day) | Response to pred. |
|---|---|---|---|---|---|---|---|---|---|
1 | 85/M | Acute myeloid leukemia -M2 | 6 months | Unilateral hands | 29 | 16.9 | 25.04 | 0 | / |
2 | 75/F | Multiple myeloma (IgA, λ) | 2 years | Bilateral hands | 61.2 | 70 | 24.35 | 15 | poor |
3 | 80/M | Diffuse large B cell lymphoma | 2 months | Bilateral hands | 86 | 45.9 | 10.2 | 40 | poor |
4 | 53/M | Plasma cell leukemia | 8 months | Unilateral hands | 19 | 177.3 | 42.48 | 30 | poor |
5 | 85/F | Rectal carcinoma | 3 years | No hands | 44 | 10.4 | 17.58 | 30 | poor |
6 | 66/F | Multiple myeloma | 3months | Bilateral hands | 71 | 26.11 | 10.94 | 15 | good |
7 | 83/M | Non-Hodgkin lymphoma | 2 months | Bilateral hands | 67 | 101 | 5.57 | 15 | good |
8 | 73/M | Lung carcinoma | 2 years | bilateral hands | 5 | 9.39 | 6.63 | 7.5 | good |